Compare Petróleo Brasileiro SA (PBR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs Vertex Pharmaceuticals Incorporated — how do they compare? Petróleo Brasileiro SA trades at $18.93 (market cap $112.59B), while Vertex Pharmaceuticals Incorporated trades at $472.52 (market cap $122.33B). The key difference: Petróleo Brasileiro SA and Vertex Pharmaceuticals Incorporated are close in size by market cap, and Petróleo Brasileiro SA pays a 9.51% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| PBR | VRTX | |
|---|---|---|
Market Cap | $112.59B | $122.33B |
Sector | Technology | Health |
52-Week High | $22.03 | $529.59 |
52-Week Low | $11.54 | $366.54 |
Enterprise Value | $176.05B | $117.07B |
Dividend Yield | 9.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PBR trades at $18.19, up 1.22% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a low P/E of 5.73 and robust profitability, including a 21.47% net income margin. Recent news highlights expansion in deepwater operations and strategic partnerships, while earnings have mostly beaten expectations except for a Q1 2026 miss.
The outlook is positive, supported by attractive valuation, solid cash flows, and dividend payments. Risks include oil price volatility and execution of new projects. Analyst consensus leans bullish with 50% buy ratings, but overbought RSI levels suggest near-term caution.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
